atazanavir sulfate has been researched along with omeprazole in 11 studies
| Studies (atazanavir sulfate) | Trials (atazanavir sulfate) | Recent Studies (post-2010) (atazanavir sulfate) | Studies (omeprazole) | Trials (omeprazole) | Recent Studies (post-2010) (omeprazole) |
|---|---|---|---|---|---|
| 1,102 | 246 | 590 | 9,085 | 2,737 | 1,487 |
| Protein | Taxonomy | atazanavir sulfate (IC50) | omeprazole (IC50) |
|---|---|---|---|
| Mcl-1 | Homo sapiens (human) | 3.1448 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.28 | |
| Potassium-transporting ATPase alpha chain 1 | Homo sapiens (human) | 1.45 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 2.315 | |
| Potassium-transporting ATPase subunit beta | Homo sapiens (human) | 1.45 | |
| WD repeat-containing protein 5 | Homo sapiens (human) | 1.7 | |
| Glutathione S-transferase omega-1 | Homo sapiens (human) | 4.6 | |
| Histone-lysine N-methyltransferase 2A | Homo sapiens (human) | 1.7 | |
| Muscarinic acetylcholine receptor | Cavia porcellus (domestic guinea pig) | 3.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (81.82) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Collier, AC; Kosel, BW; Storey, SS | 1 |
| Bednarczyk, E; Berenson, CS; Difrancesco, R; Eberhardt, E; Morse, GD; Ogundele, AB; Smith, PF; Tomilo, DL | 1 |
| Crum, NF; Furtek, KJ; Olson, PE; Wallace, MR | 1 |
| Chan-Tack, KM; Edozien, A | 1 |
| Ballard, C; Best, B; Caperna, J; Capparelli, E; Goicoechea, M; Haubrich, R | 1 |
| Brower, R; Frank, I; Kim, D; Luber, AD; Peloquin, CA; Silverman, R | 1 |
| Beck, K; Cai, Y; Causemaker, SJ; Chiu, YL; Doan, T; Esslinger, HU; Hanna, GJ; King, KR; Klein, CE; Podsadecki, TJ | 1 |
| Agarwala, S; Bertz, R; Dragone, J; Eley, T; Li, T; Mahnke, L; Persson, A; Xu, X; Zhu, L | 1 |
| Bendayan, R; Kis, O; Walmsley, SL | 1 |
3 trial(s) available for atazanavir sulfate and omeprazole
| Article | Year |
|---|---|
Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Atazanavir Sulfate; Cross-Over Studies; Drug Antagonism; Female; Gastric Acid; HIV Protease Inhibitors; Humans; Intestinal Absorption; Lansoprazole; Male; Oligopeptides; Omeprazole; Proton Pump Inhibitors; Pyridines | 2006 |
Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
Topics: Adult; Anti-HIV Agents; Anti-Ulcer Agents; Area Under Curve; Atazanavir Sulfate; Biological Availability; Dose-Response Relationship, Drug; Drug Interactions; Female; Histamine H2 Antagonists; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Omeprazole; Pyridines; Pyrimidinones; Ranitidine; Ritonavir | 2008 |
Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.
Topics: Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Atazanavir Sulfate; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Omeprazole; Proton Pump Inhibitors; Pyridines; Ritonavir | 2011 |
8 other study(ies) available for atazanavir sulfate and omeprazole
| Article | Year |
|---|---|
Atazanavir not to be used with proton pump inhibitors.
Topics: Anti-HIV Agents; Anti-Ulcer Agents; Atazanavir Sulfate; Drug Interactions; Humans; Oligopeptides; Omeprazole; Proton Pump Inhibitors; Pyridines | 2005 |
Lack of interaction between atazanavir and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Atazanavir Sulfate; Contraindications; Drug Interactions; Drug Therapy, Combination; Gastroesophageal Reflux; HIV Infections; Humans; Lansoprazole; Male; Oligopeptides; Omeprazole; Proton Pump Inhibitors; Pyridines | 2005 |
FDA notifications. BMS issues letter about omeprazole.
Topics: Area Under Curve; Atazanavir Sulfate; Drug Industry; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Oligopeptides; Omeprazole; Pyridines; Randomized Controlled Trials as Topic; Ritonavir; United States; United States Food and Drug Administration | 2005 |
Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzimidazoles; Contraindications; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Omeprazole; Proton Pump Inhibitors; Pyridines; Rabeprazole; Ritonavir | 2006 |
Ritonavir-boosted atazanavir may be efficacious in HIV-infected patients concurrently receiving omeprazole.
Topics: Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Omeprazole; Pyridines; Ritonavir | 2006 |
Therapeutic ritonavir-boosted atazanavir plasma concentration and concurrent omeprazole use.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Interactions; Drug Monitoring; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Omeprazole; Proton Pump Inhibitors; Pyridines; Ritonavir | 2006 |
Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Male; Oligopeptides; Omeprazole; Organophosphates; Proton Pump Inhibitors; Pyridines; Sulfonamides | 2007 |
In Vitro and In Situ evaluation of pH-dependence of atazanavir intestinal permeability and interactions with acid-reducing agents.
Topics: Acids; Animals; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Drug Interactions; Eating; HIV Infections; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Intestinal Mucosa; Intestines; Male; Oligopeptides; Omeprazole; Permeability; Proton Pump Inhibitors; Pyridines; Rats, Sprague-Dawley; Reducing Agents | 2014 |